Program Medium 
Internet-based program

Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period June 10, 2020 through June 10, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 31 segments, totaling 2.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity
2.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the ability to optimize the management of atopic dermatitis in children, adolescents and adults.

Release Date
June 10, 2020

Expiration Date
June 10, 2022

Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for pediatric, adolescent and adult patients who may have atopic dermatitis, including adult and pediatric dermatology specialists, allergists, immunologists, pediatricians, family medicine specialists, and related clinicians.

Registration
Participation in this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals. 

Grantor Support
This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine, and CMEducation Resources, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Policy on Faculty & Provider Disclosure

It is the policy of the Postgraduate Institute for Medicine to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the Postgraduate Institute for Medicine are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.  
Program Faculty and Disclosure

Lawrence Eichenfield, MD
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine
San Diego, California

Consultant: Allergan Plc; Anacor Pharmaceuticals Inc.; Dermavant Sciences, Inc.; Dermira, Inc.; DS Biopharma Limited; Eli Lilly and Company; Forté Pharma Laboratories; Galderma Laboratories, L.P.; Incyte Corporation; LEO Pharma, Inc.; MatriSys Bioscience, Inc.; Medimetriks Pharmaceuticals, Inc.; Menlo Therapeutics Inc.; Novan, Inc.; Novartis AG; Ortho Dermatologics, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme; TopMD; DSM: Glenmark Pharmaceuticals Inc.

Investigator: LEO Pharma, Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme; Advisory Board: Ortho Dermatologics, Inc. Equity Options: TopMD

Honoraria: Allergan Plc; Anacor Pharmaceuticals Inc.; Dermavant Sciences, Inc.; Dermira, Inc.; DS Biopharma Limited; Eli Lilly and Company; Forté Pharma Laboratories; Galderma Laboratories, L.P.; Glenmark Pharmaceuticals Inc.; Incyte Corporation; LEO Pharma, Inc.; MatriSys Bioscience, Inc.; Medimetriks Pharmaceuticals, Inc.; Menlo Therapeutics Inc.; Novan, Inc.; Novartis AG; Ortho Dermatologics, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme

Speakers Bureau: Ortho Dermatologics, Inc.

Mark G. Lebwohl, MD
Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

An employee of the Mount Sinai Medical Center which receives research funds from AbbVie Inc.; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Boehringer Ingleheim; Celgene Corporation; Eli Lilly and Company; Janssen Research & Development, LLC; Kadmon Holdings, Inc.; Medimmune/Astra Zeneca; Novartis; Pfizer Inc.; and Vidac.

Peter Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Advisory Board: Johnson & Johnson, DermTap, Intraderm, Regeneron, Sanofi US, Realm Pharmaceuticals, Menlo Therapeutics, Syncere Skin Systems, DermVeta, gpower Inc., UCB, Altus Labs, Arbonne

Speaker: Pierre Fabre Dermatologie, Regeneron, Pfizer, Roche

Consultant: Exeltis, Theraplex, Odeza, L’Oreal, Franklin BioScience, Abbvie, Eli Lilly, Unilever, Leo

Program Managers and Web Editor Disclosure 
Program Manager Gideon Bosker, MD  has nothing to disclose.

Educational Objectives
Upon completion of this activity, participants will be able to:

• Outline the practical aspects of deploying systemic biologic therapy in adult, adolescent, and pediatric patients with AD, including patient selection and identification, dosing, monitoring, side effects, expected outcomes, and duration of use for agents inhibiting T2 signaling cytokines involved in producing inflammation and symptoms of AD;
• Detail the scientific and medical aspects of cytokine-based therapeutic targets, lifelong disease burden in AD, disease classification and severity scales and evidence-based/FDA-approved therapies for moderate-to-severe AD and related atopic conditions in children, adolescents, and adults;
• Describe the pathoimmunobiology of AD and related Type 2 cytokine-mediated conditions, including the pivotal role of IL-4 and IL-13 in AD and associated atopic disease states; and how approved biologic therapies target these cytokines in adolescent and adult patients when clinically appropriate and indicated;
• Deploy FDA-approved biologic-based treatments that are cytokine-centric, with appropriate consideration for dosing, indications, safety, duration of therapy, side effects, clinical triggers, and efficacy of such biologic treatments;
• Outline the immunological aspects of AD and related atopic disease states and, in particular, the immune-based humoral and cellular biomarkers, phenotypic profiles, and genotypic and phenotypic signatures associated with AD and related conditions, to help identify optimal treatment roadmaps associated with such biomarkers

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2020 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC